114 related articles for article (PubMed ID: 35994989)
1. Functionalized bosutinib liposomes for target specific delivery in management of estrogen-positive cancer.
Singh P; Singh N; Mishra N; Nisha R; Alka ; Maurya P; Pal RR; Singh S; Saraf SA
Colloids Surf B Biointerfaces; 2022 Oct; 218():112763. PubMed ID: 35994989
[TBL] [Abstract][Full Text] [Related]
2. Appraisal of folate functionalized bosutinib cubosomes against hepatic cancer cells: In-vitro, In-silico, and in-vivo pharmacokinetic study.
Nisha R; Kumar P; Mishra N; Maurya P; Ahmad S; Singh N; Saraf SA
Int J Pharm; 2024 Apr; 654():123975. PubMed ID: 38452833
[TBL] [Abstract][Full Text] [Related]
3. Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Moy B; Neven P; Lebrun F; Bellet M; Xu B; Sarosiek T; Chow L; Goss P; Zacharchuk C; Leip E; Turnbull K; Bardy-Bouxin N; Duvillié L; Láng I
Oncologist; 2014 Apr; 19(4):346-7. PubMed ID: 24674873
[TBL] [Abstract][Full Text] [Related]
4. Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB
Luo Q; Gong P; Sun M; Kou L; Ganapathy V; Jing Y; He Z; Sun J
J Control Release; 2016 Dec; 243():370-380. PubMed ID: 27810556
[TBL] [Abstract][Full Text] [Related]
5. Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Moy B; Neven P; Lebrun F; Bellet M; Xu B; Sarosiek T; Chow L; Goss P; Zacharchuk C; Leip E; Turnbull K; Bardy-Bouxin N; Duvillié L; Láng I
Oncologist; 2014 Apr; 19(4):348-9. PubMed ID: 24674874
[TBL] [Abstract][Full Text] [Related]
6. Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy.
Salkho NM; Paul V; Kawak P; Vitor RF; Martins AM; Al Sayah M; Husseini GA
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):462-472. PubMed ID: 29644867
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.
Redaelli S; Perini P; Ceccon M; Piazza R; Rigolio R; Mauri M; Boschelli F; Giannoudis A; Gambacorti-Passerini C
J Hematol Oncol; 2015 Jul; 8():81. PubMed ID: 26149173
[TBL] [Abstract][Full Text] [Related]
8. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
[TBL] [Abstract][Full Text] [Related]
9. Design, preparation and evaluation of different branched biotin modified liposomes for targeting breast cancer.
Tang B; Peng Y; Yue Q; Pu Y; Li R; Zhao Y; Hai L; Guo L; Wu Y
Eur J Med Chem; 2020 May; 193():112204. PubMed ID: 32172035
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo Evaluation of a Novel Estrogen-Targeted PEGylated Oxaliplatin Liposome for Gastric Cancer.
Sun Y; Xie Y; Tang H; Ren Z; Luan X; Zhang Y; Zhu M; Lv Z; Bao H; Li Y; Liu R; Shen Y; Zheng Y; Pei J
Int J Nanomedicine; 2021; 16():8279-8303. PubMed ID: 34992365
[TBL] [Abstract][Full Text] [Related]
11. PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Shavi GV; Sreenivasa Reddy M; Raghavendra R; Nayak UY; Kumar AR; Deshpande PB; Udupa N; Behl G; Dave V; Kushwaha K
J Liposome Res; 2016; 26(1):28-46. PubMed ID: 25853340
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation.
Jain AS; Goel PN; Shah SM; Dhawan VV; Nikam Y; Gude RP; Nagarsenker MS
Biomed Pharmacother; 2014 May; 68(4):429-38. PubMed ID: 24721327
[TBL] [Abstract][Full Text] [Related]
13. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
14. Fructose and biotin co-modified liposomes for dual-targeting breast cancer.
Li R; Peng Y; Pu Y; Zhao Y; Nie R; Guo L; Wu Y
J Liposome Res; 2022 Jun; 32(2):119-128. PubMed ID: 34895001
[TBL] [Abstract][Full Text] [Related]
15. Bosutinib for the treatment of chronic myeloid leukemia.
Doan V; Wang A; Prescott H
Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
[TBL] [Abstract][Full Text] [Related]
16. PEGylated liposomes as delivery systems for Gambogenic acid: Characterization and in vitro/in vivo evaluation.
Tang X; Sun J; Ge T; Zhang K; Gui Q; Zhang S; Chen W
Colloids Surf B Biointerfaces; 2018 Dec; 172():26-36. PubMed ID: 30125771
[TBL] [Abstract][Full Text] [Related]
17. Preparation, Characterization, and In Vitro Pharmacodynamics and Pharmacokinetics Evaluation of PEGylated Urolithin A Liposomes.
Yi S; Zhang C; Hu J; Meng Y; Chen L; Yu H; Li S; Wang G; Zheng G; Qiu Z
AAPS PharmSciTech; 2021 Jan; 22(1):26. PubMed ID: 33404864
[TBL] [Abstract][Full Text] [Related]
18. Tumor microenvironment responsive VEGF-antibody functionalized pH sensitive liposomes of docetaxel for augmented breast cancer therapy.
Jain S; Deore SV; Ghadi R; Chaudhari D; Kuche K; Katiyar SS
Mater Sci Eng C Mater Biol Appl; 2021 Feb; 121():111832. PubMed ID: 33579470
[TBL] [Abstract][Full Text] [Related]
19.
Hu S; Xie D; Zhou P; Liu X; Yin X; Huang B; Guan H
Int J Mol Med; 2021 May; 47(5):. PubMed ID: 33693953
[TBL] [Abstract][Full Text] [Related]
20. Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7.
Gandhi R; Khatri N; Baradia D; Vhora I; Misra A
Drug Deliv; 2016 May; 23(4):1152-62. PubMed ID: 25586675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
